Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of SAR442720 in Combination With Other Agents in Participants With Advanced Malignancies

NCT04418661 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT04418661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04418661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of SAR442720 in Combination With Other Agents in Participants With Advanced Malignancies
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Terminated
Start date
June 9, 2020
Completion date
April 4, 2024
Enrollment
65 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic neoplasm